Overcoming drug resistance in hormone-and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination

Simple item page
dc.contributor.authorCengiz E.
dc.contributor.authorKaraca B.
dc.contributor.authorKucukzeybek Y.
dc.contributor.authorGorumlu G.
dc.contributor.authorGul M.K.
dc.contributor.authorErten C.
dc.contributor.authorAtmaca H.
dc.contributor.authorUzunoglu S.
dc.contributor.authorKarabulut B.
dc.contributor.authorSanli U.A.
dc.contributor.authorUslu R.
dc.date.accessioned2025-04-10T11:15:46Z
dc.date.available2025-04-10T11:15:46Z
dc.date.issued2010
dc.description.abstractDrug resistance is a significant challenge of daily oncology practice. Docetaxel and gossypol both have antitumoral activity in hormone-refractory prostate cancer (HRPC). Our results revealed that docetaxel and gossypol were synergistically cytotoxic and apoptotic in PC-3 cells in a dose-and time-dependent manner. We further investigated the expression profiles of genes involved in drug resistance and metabolism with a Human Cancer Drug Resistance and Metabolism PCR Array® (SuperArray). Six of the 84 genes that are known to regulate drug resistance, metabolism, cell cycle, DNA repair and oncogenesis were downregulated C3-fold change by the combination treatment. These results may be important in devising mechanism-based and targeted therapeutic strategies for prostate cancer, especially in devising combination therapy for drug resistant prostate cancers. © Springer Science+Business Media B.V. 2009.
dc.identifier.DOI-ID10.1007/s11033-009-9501-y
dc.identifier.urihttp://hdl.handle.net/20.500.14701/51290
dc.titleOvercoming drug resistance in hormone-and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination
dc.typeArticle

Files

Collections

Scopus Koleksiyonu